Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EpCAM/anti-CD3 bispecific antibody A-337

A T-cell engager (TCE) and bispecific antibody composed of two fragments targeting the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326) and one targeting the T-cell surface glycoprotein CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody A-337 targets and binds to EpCAM on EpCAM-expressing tumor cells and CD3 on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.
Synonym:anti-EpCAM/anti-EpCAM/anti-CD3 bispecific antibody A-337
EpCAM x EpCAM x CD3 bispecific antibody A-337
Itab A-337
recombinant anti-EpCAM-CD3 antibody A-337
Code name:A 337
A-337
A337
Search NCI's Drug Dictionary